These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 33538213)

  • 1. Sarcosine as an add-on treatment to antipsychotic medication for people with schizophrenia: a systematic review and meta-analysis of randomized controlled trials.
    Marchi M; Galli G; Magarini FM; Mattei G; Galeazzi GM
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):483-493. PubMed ID: 33538213
    [No Abstract]   [Full Text] [Related]  

  • 2. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.
    Singh SP; Singh V
    CNS Drugs; 2011 Oct; 25(10):859-85. PubMed ID: 21936588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials.
    Chang CH; Lin CH; Liu CY; Chen SJ; Lane HY
    J Psychopharmacol; 2020 May; 34(5):495-505. PubMed ID: 32122256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of
    Goh KK; Wu TH; Chen CH; Lu ML
    J Psychopharmacol; 2021 Mar; 35(3):236-252. PubMed ID: 33406959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
    Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
    Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
    Tsai G; Lane HY; Yang P; Chong MY; Lange N
    Biol Psychiatry; 2004 Mar; 55(5):452-6. PubMed ID: 15023571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
    Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
    World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
    Lane HY; Lin CH; Huang YJ; Liao CH; Chang YC; Tsai GE
    Int J Neuropsychopharmacol; 2010 May; 13(4):451-60. PubMed ID: 19887019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, tolerability and pharmacokinetics of open label sarcosine added on to anti-psychotic treatment in schizophrenia - preliminary study.
    Amiaz R; Kent I; Rubinstein K; Sela BA; Javitt D; Weiser M
    Isr J Psychiatry Relat Sci; 2015; 52(1):12-5. PubMed ID: 25841105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia.
    Lane HY; Huang CL; Wu PL; Liu YC; Chang YC; Lin PY; Chen PW; Tsai G
    Biol Psychiatry; 2006 Sep; 60(6):645-9. PubMed ID: 16780811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia.
    Strzelecki D; Kałużyńska O; Szyburska J; Wlazło A; Wysokiński A
    Psychiatry Res; 2015 Dec; 230(2):200-4. PubMed ID: 26343833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of TNF-alpha in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the PULSAR study).
    Strzelecki D; Urban-Kowalczyk M; Wysokiński A
    Psychiatry Res; 2018 Oct; 268():447-453. PubMed ID: 30130712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A possible role for sarcosine in the management of schizophrenia.
    Curtis D
    Br J Psychiatry; 2019 Dec; 215(6):697-698. PubMed ID: 31685041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis.
    Tsai GE; Lin PY
    Curr Pharm Des; 2010; 16(5):522-37. PubMed ID: 19909229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence.
    Correll CU; Rubio JM; Inczedy-Farkas G; Birnbaum ML; Kane JM; Leucht S
    JAMA Psychiatry; 2017 Jul; 74(7):675-684. PubMed ID: 28514486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MMP-9 Serum Levels in Schizophrenic Patients during Treatment Augmentation with Sarcosine (Results of the PULSAR Study).
    Strzelecki D; Kałużyńska O; Szyburska J; Wysokiński A
    Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27409603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis.
    Vayısoğlu S; Karahan S; Anıl Yağcıoğlu AE
    Turk Psikiyatri Derg; 2019; 30(4):253-259. PubMed ID: 32594486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
    Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
    Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.